Base de dados : LILACS
Pesquisa : D27.505.519.389.320 [Categoria DeCS]
Referências encontradas : 7 [refinar]
Mostrando: 1 .. 7   no formato [Detalhado]

página 1 de 1

  1 / 7 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1045772
Autor: Wang, Congcong; Pang, Shuguang; Jiang, Qiang; Duan, Guanglan; Sun, Yongmei; Li, Mei.
Título: Treatment with acarbose in severe hypoglycaemia due to late dumping syndrome / Tratamiento con acarbosa en la hipoglicemia severa debido al síndrome de dumping tardío
Fonte: West Indian med. j;62(9):861-863, Dec. 2013. graf, tab.
Idioma: en.
Projeto: National Natural Science Foundation of China; . Science and Technology Development Programme of Shandong; . International Cooperation Programme of Jinan City.
Resumo: BACKGROUND: We present a case of recurrent loss of consciousness, which was finally accurately diagnosed as late dumping syndrome twelve years after subtotal gastrectomy and successfully treated with acarbose. A 66-year old lean male was found unconscious repeatedly within one year. Oral glucose tolerance tests performed before and after acarbose treatment verified the diagnosis of late dumping syndrome. Acarbose can be used as a successful treatment modality for reactive hypoglycaemia due to late dumping syndrome by influencing the release of hormone.

ANTECEDENTES: Presentamos un caso de pérdida recurrente de conciencia, que fue finalmente diagnosticado con precisión como síndrome de dumping tardío, doce años después de la gastrectomía subtotal, y tratado con éxito con acarbosa. Un hombre magro de 66 años de edad fue encontrado inconsciente repetidas veces en un año. Las pruebas orales de tolerancia a la glucosa realizadas antes y después del tratamiento con acarbosa verificaron el diagnóstico de síndrome de dumping tardío. La acarbosa puede utilizarse como una modalidad de tratamiento acertado para la hipoglicemia reactiva debido al síndrome de dumping tardío por la influencia en la liberación de hormonas.
Descritores: Acarbose/uso terapêutico
Síndrome de Esvaziamento Rápido/complicações
Inibidores de Glicosídeo Hidrolases/uso terapêutico
Hipoglicemia/etiologia
Hipoglicemia/tratamento farmacológico
Limites: Humanos
Masculino
Idoso
Tipo de Publ: Relatos de Casos
Responsável: BR1.1 - BIREME


  2 / 7 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1129064
Autor: Carlucci, Adriana M; Cervellera, Camila P; De Sa Sampayo, Caroline M; De Vito, Antonella; Villafañe, Cristian A; Martín, Carolina J; Sterin Prync, Aída E; Schreck, Carlos M.
Título: Aportes de la biotecnología al diagnóstico y tratamiento de la enfermedad renal crónica y comorbilidades frecuentes / Biotechnology contribution to the diagnosis and treatment of chronic kidney disease and frequent comorbidities
Fonte: Rev. Hosp. Ital. B. Aires (2004);40(3):105-116, sept. 2020. ilus, tab.
Idioma: es.
Resumo: Este trabajo tiene como objetivo revisar las contribuciones de la biotecnología, en relación con el tratamiento, diagnóstico y la monitorización de la enfermedad renal crónica (ERC) y sus comorbilidades más frecuentes, especialmente la anemia. En relación con los tratamientos, enfocamos el desarrollo de productos biofarmacéuticos como los agentes estimulantes de la eritropoyesis (ESA), que fueron los primeros biofármacos utilizados para el tratamiento de la anemia asociada a la ERC; analizamos sus características y utilización actual después de varios años de experiencia clínica, así como también otras alternativas en desarrollo. Revisamos distintos tipos de bioterapias, la utilización de las células estromales mesenquimales de médula ósea (MSC) y tratamientos alternativos con modificaciones dietarias, que se basan en la asociación entre la microbiota intestinal de los pacientes renales crónicos y sus condiciones fisiopatológicas. Finalmente, en relación con el diagnóstico y monitorización, nos referimos al estudio y validación de biomarcadores diagnósticos, predictivos y terapéuticos que han permitido optimizar los resultados clínicos en este tipo de pacientes. (AU)

The aim of this work is to review the contributions of biotechnology, in relation to the treatment, diagnosis and monitoring of chronic kidney disease (CKD) and its most frequent comorbidities, especially anemia. Regarding the treatment, we focus on the development of biopharmaceutical products such as erythropoiesis stimulating agents (ESA), which were the first biopharmaceuticals used to treat anemia associated with chronic kidney disease (CKD). We analyzed their characteristics and their current use after several years of clinical experience, as well as other alternatives in development. We also review different types of biotherapies, the use of bone marrow mesenchymal stromal cells (MSC) and alternative treatments with dietary modifications, which are based on the association between the intestinal microbiota of chronic kidney patients and their pathophysiological conditions. Finally, in relation to diagnosis and monitoring, we refer to the study and validation of diagnostic, predictive and therapeutic biomarkers that have made clinical results possible to be optimized in this type of patient. (AU)
Descritores: Terapia Biológica/tendências
Insuficiência Renal Crônica/terapia
-Qualidade de Vida
Biotecnologia
Biomarcadores
Eritropoetina/deficiência
Probióticos/uso terapêutico
Transplante de Células-Tronco Mesenquimais/tendências
Eritropoese/efeitos dos fármacos
Insuficiência Renal Crônica/diagnóstico
Insuficiência Renal Crônica/dietoterapia
Insuficiência Renal Crônica/reabilitação
Prebióticos/classificação
Inibidores de Glicosídeo Hidrolases/uso terapêutico
Microbioma Gastrointestinal
Hematínicos/administração & dosagem
Hematínicos/farmacologia
Hematínicos/farmacocinética
Anemia/diagnóstico
Anemia/etiologia
Anemia/tratamento farmacológico
Limites: Humanos
Tipo de Publ: Revisão
Responsável: AR2.1 - Biblioteca Central


  3 / 7 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-1119223
Autor: FERNANDES, Kamila Rangel Primo; BITTERCOURT, Paulo Senna; SOUZA, Afonso Duarte Leão de; SOUZA, Antonia Queiroz Lima de; SILVA, Felipe Moura Araújo da; LIMA, Emerson Silva; ACHO, Leonard Domingo Rosales; NUNOMURA, Rita de Cássia Saraiva; TEIXEIRA, Ana Frazão; KOOLEN, Hector Henrique Ferreira.
Título: Phenolic compounds from Virola venosa (Myristicaceae) and evaluation of their antioxidant and enzyme inhibition potential
Fonte: Acta amaz;49(1):48-53, jan. - mar. 2019.
Idioma: en.
Resumo: Virola venosa, popularly known in Brazil as ucuuba-da-mata, occurs naturally in the Amazon region and has potential to provide useful natural compounds, as already known for other Virola species. Therefore, the objective of this study was to determine the chemical composition of bark and leaf extracts of V. venosa, and to test the antioxidant capacity and α-glucosidase inhibition potential of their compounds. Polar extracts showed to be more active in both assays, therefore a bioactivity-guided fractionation was performed to identify the compounds that were responsible for the recorded activities. Using a combination of LC-MS/MS analysis and isolation with NMR identification, eight phenolic compounds were identified. Assays with pure compounds of the active fraction revealed that ferulic acid was the main contributor compound to the observed bioactivity in the crude extracts. (AU)
Descritores: Ecossistema Amazônico
Compostos Fenólicos
Inibidores de Glicosídeo Hidrolases
Antioxidantes
Responsável: BR6.1 - BCS - Biblioteca de Ciências da Saúde


  4 / 7 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Texto completo
Id: biblio-1019533
Autor: Abbasi, Muhammad Athar; Riaz, Sajid; Rehman, Aziz-ur-; Siddiqui, Sabahat Zahra; Shah, Syed Adnan Ali; Ashraf, Muhammad; Lodhi, Muhammad Arif; Khan, Farman Ali.
Título: Synthesis of new 2-{2,3-dihydro-1, 4-benzodioxin-6-yl[(4-methylphenyl) sulfonyl]amino}-N-(un/substituted-phenyl)acetamides as α-glucosidase and acetylcholinesterase inhibitors and their in silico study
Fonte: Braz. J. Pharm. Sci. (Online);55:e17032, 2019. tab, graf.
Idioma: en.
Resumo: The aim of the present research work was to investigate the enzyme inhibitory potential of some new sulfonamides having benzodioxane and acetamide moieties. The synthesis was started by the reaction of N-2,3-dihydrobenzo[1,4]-dioxin-6-amine (1) with 4-methylbenzenesulfonyl chloride (2) in the presence of 10% aqueous Na2CO3 to yield N-(2,3-dihydrobenzo[1,4]-dioxin-6-yl)-4-methylbenzenesulfonamide (3), which was then reacted with 2-bromo-N-(un/substituted-phenyl)acetamides (6a-l) in DMF and lithium hydride as a base to afford various 2-{2,3-dihydro-1,4-benzodioxin-6-yl[(4-methylphenyl)sulfonyl]amino}-N-(un/substituted-phenyl)acetamides (7a-l). All the synthesized compounds were characterized by their IR and 1H-NMR spectral data along with CHN analysis data. The enzyme inhibitory activities of these compounds were tested against a-glucosidase and acetylcholinesterase (AChE). Most of the compounds exhibited substantial inhibitory activity against yeast a-glucosidase and weak against AChE. The in silico molecular docking results were also consistent with in vitro enzyme inhibition data.
Descritores: Sulfonamidas/agonistas
Inibidores da Colinesterase
Inibidores de Glicosídeo Hidrolases
-Análise Espectral/instrumentação
Acetamidas/análise
Responsável: BR40.1 - DBD - Divisão de Biblioteca e Documentacão do Conjunto das Químicas


  5 / 7 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-912038
Autor: Ponce, Jorge Orlando; Rodríguez Vigay, Nazarena; Juárez, Rolando Pablo.
Título: Inhibición de la a-amilasa por medio de extractos de plantas medicinales como tratamiento complementario/alternativo de la diabetes y la caries / Inhibition of a a-amylase by means of extracts of medicinal plants as complementary/alternative treatment of diabetes and caries
Fonte: Rev. Soc. Odontol. La Plata;28(55):41-45, mayo 2018.
Idioma: es.
Resumo: Los inhibidores selectivos de la α-amilasa salival y pancreática humana, son un medio eficaz para controlar los niveles de azúcar en la saliva y la sangre, durante el control de la caries y la diabetes. En la presente revisión, después de identificar las principales funciones de la enzima, se discutieron exponen algunas de las respuestas observadas después de la exposición de la α-amilasa a las plantas, en escala molecular y entera. Diferentes tipos de moléculas de plantas medicinales actúan como inhibidores de la α-amilasa, como una terapia alternativa o complementaria en el tratamiento de la diabetes en y en el control de uno de los factores de la formación la caries (dieta) (AU)

Selective inhibitors of human salivary and pancreatic α-amylase are an effective means of controlling saliva and blood sugar levels in the management of caries and diabetes. In the present review, after identifying the main functions of the enzyme, it was exposed some of the observed responses after exposure to α-amylase at the molecular and whole plants scale. Different types of medicinal plants molecules have been found to act as α-amylase inhibitors, as an alternative or complementary therapy in the management of diabetes and control to one of the predisposing factors to caries (diet) (AU)
Descritores: alfa-Amilases
Cárie Dentária
Diabetes Mellitus
Inibidores Enzimáticos
Plantas Medicinais
-Terapias Complementares
Inibidores de Glicosídeo Hidrolases
Limites: Humanos
Tipo de Publ: Técnicas In Vitro
Responsável: AR29.1 - Biblioteca


  6 / 7 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-907510
Autor: Cristians, Sol; Osuna-Fernández, H. Reyna; Ramírez-Ávila, Guillermo; Muñóz-Ocotero, Verónica; Laguna-Hernández, Guillermo; Brechú-Franco, Alicia E.
Título: Euphorbia dioeca Kunth as a novel source for alpha-glucosidase inhibitors / Euphorbia dioeca Kunth como una nueva fuente de inhibidores de alfa-glucosidasa
Fonte: Bol. latinoam. Caribe plantas med. aromát;14(6):483-490, Nov. 2015. tab, ilus.
Idioma: en.
Projeto: PAPIIT-UNAM.
Resumo: Euphorbia dioeca Kunth belongs to the Wanderer's herb complex that is traditionally used for skin diseases and recently as antidiabetic. The methanol and aqueous extracts were evaluated for their in vitro alpha-glucosidase inhibitory activity and an oral starch tolerance test. These extracts showed an IC50 of 0.55 and 0.85 mg/mL, respectively. In diabetic Long Evans rats, the methanol and aqueous extracts reduced significantly the postprandial hyperglycemia peak in 15.2 percent and 12.8 percent, respectively. The alpha-glucosidase inhibitory activity is related with the presence of glycosides, phenolic compounds and flavonoids. Additionally, the safety parameters of both extracts were assessed by means of an acute toxicity test, being classified as innocuous. The traditional use of E. dioeca to control type 2 diabetes was confirmed, being an important source of alfa-glucosidase inhibitors.

Euphorbia dioeca Kunth, pertenece al complejo de plantas medicinales denominado Hierba de la Golondrina; el cual se utiliza para diversos padecimientos, destacando su uso como antidiabético. En dicho marco, se evaluó tanto la actividad inhibitoria de alfa-glucosidasa in vitro, como su desempeño en una prueba de tolerancia a una carga de almidón postprandial. Los extractos inhibieron la actividad de la alfa-glucosidasa con una CI50 de 0.55 y 0.85 mg/mL, respectivamente. Los extractos metanólico y acuoso disminuyeron significativamente el pico hiperglucémico postprandial en un 15.2 por ciento y un 12.8 por ciento, respectivamente, cuando se evaluó en ratas diabéticas. La actividad inhibitoria de alfa-glucosidasa, reflejada en ambas pruebas, está relacionada con la presencia de glicósidos, compuestos fenólicos y flavonoides. De manera adicional, ambos extractos fueron evaluados en una prueba de toxicidad aguda, siendo clasificados como inocuos. Se corroboró el uso tradicional de E. dioeca para el control de la diabetes tipo 2, siendo una importante fuente de compuestos inhibidores de alfa-glucosidasa.
Descritores: /tratamento farmacológico
DIABETES MELLITUS, TYPE TEMEFOS/tratamento farmacológico
Euphorbia/química
Inibidores de Glicosídeo Hidrolases/farmacologia
Extratos Vegetais/farmacologia
-Hiperglicemia/tratamento farmacológico
Camundongos Endogâmicos BALB C
Limites: Animais
Camundongos
Responsável: CL1.1 - Biblioteca Central


  7 / 7 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Antunes, Edson
Texto completo
Id: lil-741624
Autor: Soeiro-Pereira, Paulo Vítor; Falcai, Angela; Kubo, Christina Arslanian; Antunes, Edson; Condino-Neto, Antonio.
Título: BAY 41-2272 activates host defence against local and disseminated Candida albicans infections
Fonte: Mem. Inst. Oswaldo Cruz;110(1):75-85, 03/02/2015. graf.
Idioma: en.
Resumo: In our previous study, we have found that 5-cyclopropyl-2-[1-(2-fluoro-benzyl)-1H-pyrazolo[3,4-b]pyridine-3-yl]-pyrimidin-4-ylamine (BAY 41-2272), a guanylate cyclase agonist, activates human monocytes and the THP-1 cell line to produce the superoxide anion, increasing in vitro microbicidal activity, suggesting that this drug can be used to modulate immune functioning in primary immunodeficiency patients. In the present work, we investigated the potential of the in vivo administration of BAY 41-2272 for the treatment of Candida albicans and Staphylococcus aureus infections introduced via intraperitoneal and subcutaneous inoculation. We found that intraperitoneal treatment with BAY 41-2272 markedly increased macrophage-dependent cell influx to the peritoneum in addition to macrophage functions, such as spreading, zymosan particle phagocytosis and nitric oxide and phorbol myristate acetate-stimulated hydrogen peroxide production. Treatment with BAY 41-2272 was highly effective in reducing the death rate due to intraperitoneal inoculation of C. albicans, but not S. aureus. However, we found that in vitro stimulation of peritoneal macrophages with BAY 41-2272 markedly increased microbicidal activities against both pathogens. Our results show that the prevention of death by the treatment of C. albicans-infected mice with BAY 41-2272 might occur primarily by the modulation of the host immune response through macrophage activation. .
Descritores: Adipócitos Brancos/metabolismo
Ananas/química
Suplementos Nutricionais
Frutas/química
Hipoglicemiantes/isolamento & purificação
Resíduos Industriais/análise
Extratos Vegetais/isolamento & purificação
-Adipogenia
ABATTOIRSTABATTOIRS-L1 CELLS
Adipócitos Brancos/citologia
Antioxidantes/química
Antioxidantes/economia
Antioxidantes/isolamento & purificação
Inibidores Enzimáticos/química
Inibidores Enzimáticos/economia
Inibidores Enzimáticos/isolamento & purificação
Indústria de Processamento de Alimentos/economia
Glicosilação
Glicerolfosfato Desidrogenase/antagonistas & inibidores
Glicerolfosfato Desidrogenase/metabolismo
Inibidores de Glicosídeo Hidrolases/química
Inibidores de Glicosídeo Hidrolases/economia
Inibidores de Glicosídeo Hidrolases/isolamento & purificação
Hipoglicemiantes/química
Hipoglicemiantes/economia
Índia
Resíduos Industriais/economia
Lipotrópicos/química
Lipotrópicos/economia
Lipotrópicos/isolamento & purificação
Extratos Vegetais/química
Extratos Vegetais/economia
Solventes/química
alfa-Amilases/antagonistas & inibidores
alfa-Amilases/metabolismo
Limites: Animais
Camundongos
Tipo de Publ: Estudo Comparativo
Responsável: BR1.1 - BIREME



página 1 de 1
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde